Until recently, PRP or PRF for the scalp was not much of a question. PRP had the literature, the protocols and the kits; PRF was the newer material with better release kinetics on paper and almost no head-to-head data in hair. The sensible default was PRP, and defaulting cost you nothing you could point to.
That has changed enough to make this a real decision. There is now direct comparative trial evidence in pattern hair loss, and it does not favour the default. What has not changed is the operational reason PRP became the default in the first place — and on the scalp, that reason is unusually strong.
What Tatiana Sarmiento teaches, and the protocol change attached
In Empire Medical Training's curriculum, Tatiana Sarmiento teaches that both materials are usable on the scalp — you can use PRP or PRF — with one protocol change attached to the second option. If you intend to inject PRF into the scalp, the injection has to be fast.
That is a short instruction carrying a large operational load, and it is the crux of this whole article. It is worth understanding why the scalp is the indication where that constraint bites hardest.
These figures reflect Tatiana Sarmiento's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
Why the handling penalty is worse here than anywhere else
PRF's working window is short everywhere. Fibrin polymerisation begins the moment blood contacts an additive-free tube, and the material is thickening in the syringe from the time you draw it up. That is a constraint in any indication.
The scalp makes it worse for one reason: the treatment field is enormous relative to the deposit size. A discrete tear trough or a single defect is one target that can be addressed in moments. A scalp treatment is a systematic sweep across a large surface, delivering many small deposits at close spacing, across a field that may cover most of the vertex, the frontal region, or both.
That means three things converge unhelpfully. The total procedure time is long, precisely when your material has a short clock. Delivery is through fine instrumentation into a superficial tissue plane, where a thickening material raises plunger force fastest. And the last portion of the field is treated with material that has been polymerising for the entire preceding treatment, so the deposit you make at minute ten is not the deposit you made at minute two.
There is no technique that removes this. There are only workflow decisions that manage it — smaller sequential loads rather than one large syringe, a genuinely two-person room with one person owning the blood and one owning the patient, a centrifuge in the room rather than down the corridor, and a realistic ceiling on how much field can be covered in a single preparation.
That last point is the one most likely to surprise a practice moving from PRP to PRF on the scalp: you may need to treat less area per sitting, or accept more sittings, than your PRP protocol required. It is the same workflow arithmetic that governs any combined hair programme, including one that also uses PDO threads.
What the comparative evidence now shows
Set against that operational penalty is a genuine efficacy signal, and it has become harder to dismiss.
A prospective multicentre randomised clinical trial enrolled patients with female pattern hair loss (Sinclair grade II–III) and randomised them to four sessions of PRP, injectable PRF or concentrated growth factors at four-week intervals. The primary endpoint was the between-group comparison of non-vellus target area hair count increase at 24 weeks. Seventy-four patients completed the study.
All three groups improved significantly from baseline. The differences between them were the point:
- Target area hair count increase was 26.5% for i-PRF and 27.1% for CGF, against 14.5% for PRP — a statistically significant advantage for both over PRP, with no significant difference between i-PRF and CGF.
- Hair diameter improved in all three groups with no statistically significant differences between them.
- The i-PRF group had the lowest adverse event rate.
- VEGF concentration correlated significantly with the percentage increase in target area hair count.
(Li et al., Journal of Dermatological Treatment, 2026.)
A 2026 systematic review of regenerative modalities in androgenetic alopecia, covering 20 clinical studies and 724 patients across conditioned media, PRF, stromal vascular fraction, extracellular vesicles and stem cells, reported that PRF demonstrated the fastest and most consistent responses among the modalities reviewed, with hair density improvements in the range of 62–97% within three to six months (Behrangi et al., Stem Cell Research & Therapy, 2026). Those are large numbers drawn from a heterogeneous study pool with varying baselines and measurement methods, and they should be read as a direction of effect rather than an expected outcome for your next patient.
This does not make PRP ineffective. PRP remains by a wide margin the most-studied platelet concentrate in hair loss, with a plausible mechanism through angiogenesis and Wnt/β-catenin, MAPK, Akt/ERK and Notch signalling, and improved density, thickness and satisfaction in clinical trials — particularly in combination with minoxidil, microneedling or laser (Zhong et al., Journal of Cosmetic Dermatology, 2026). The same review names the field's central problem plainly: heterogeneity in centrifugation, activation and delivery protocols produces inconsistent outcomes across studies.
That caveat cuts both ways. It weakens confidence in the PRP literature and in the newer PRF comparison alike.
How the decision actually resolves
Two honest readings sit side by side.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
The efficacy reading: direct comparative evidence in female pattern hair loss now favours injectable PRF over PRP on density gain, with a lower adverse event rate, and the wider regenerative review is consistent with that direction. If density is the endpoint the patient cares about — and it usually is — the material with the better head-to-head result deserves consideration.
The delivery reading: that result was produced in a trial setting with the material delivered inside its window. A clinic that cannot reliably do that will not reproduce it. Product selected badly and delivered well beats product selected well and delivered badly, every time.
Which leads to the practical rule. Do not switch the scalp to PRF as a product upgrade. Switch it as a workflow project, or not at all. The prerequisites are a dedicated centrifuge in or beside the room, two trained staff with separated roles, a schedule block that commits the room for the whole procedure, and a validated sense of your own working window with your own tubes — silica-coated tubes solidify substantially faster than plain plastic, so the consumable you buy sets your clock.
If those four are in place, the comparative data justify PRF. If any is missing, PRP delivered properly remains the better clinical decision, and there is nothing apologetic about that.
The variable underneath both options
There is a third selection axis that sits beneath the PRP-or-PRF question and is almost never audited: leukocyte content.
The standard classification of platelet concentrates sorts them on two independent axes — fibrin architecture and leukocyte content — so both PRP and PRF exist in pure and leukocyte-rich forms. Leukocyte-rich preparations carry neutrophils and monocytes into the treatment site and with them an inflammatory contribution. A 2025 scoping review of regenerative therapies in androgenetic alopecia noted that newer leukocyte-rich and pure PRP formulations are an active area of investigation, and that recent studies remain limited by inconsistent reporting of cellular composition, short follow-up and a lack of comparative protocol data (Gupta et al., Medical Sciences, 2025).
The practical point for a scalp practice: if your outcomes differ from a published series, the explanation may not be PRP-versus-PRF at all. It may be that your kit produces a materially different cell population from theirs, under the same product name. Find out which variant yours makes before you attribute a result, good or bad, to the choice between the two families.
Setting the timeline expectation
Terminal scalp hair grows at approximately 0.35 mm per day — on the order of 1 to 1.25 cm per month. Shaft elongation, in other words, is not what the patient is waiting for.
What they are waiting for is follicular cycling. The intervention acts by recruiting follicles back toward anagen and improving calibre in miniaturised ones, and cycling takes months to express. That is why around month three is the earliest honest reassessment point, and it is a far more durable explanation than any growth-rate figure — it survives the patient looking it up, and it makes the three-month review make sense rather than sound arbitrary. It is also part of the wider collagen and tissue-remodelling conversation you are already having with these patients.
What this article is not deciding for you
Diagnosis comes before material selection and outranks it. Pattern hair loss, telogen effluvium, scarring alopecia and hair loss driven by thyroid, iron or hormonal causes are different problems, and no platelet concentrate substitutes for establishing which one is in front of you. Neither PRP nor PRF is a treatment for a diagnosis you have not made.
Mapping the scalp, photographic baselines, injection spacing and depth, session counts and maintenance intervals are all protocol questions with their own answers. This piece answers one narrower question — which material — and it answers it as a trade rather than a winner.
Empire Medical Training's Medical Hair Loss, PDO Threads and PRP Hair Restoration workshop covers hair restoration using platelet concentrates and threads under supervision, and Platelet Rich Plasma Training covers preparation and application more broadly. For how platelet concentrates compare with other regenerative agents, see exosomes, PDRN and PRP.
Frequently Asked Questions
Is PRF now better than PRP for hair loss?
A multicentre randomised trial in female pattern hair loss found injectable PRF produced a significantly greater increase in target area hair count than PRP at 24 weeks — roughly 27% against 15% — with a lower adverse event rate. That is one trial in one population, and delivery quality matters as much as material choice, so it is a reason to reconsider the default rather than to abandon PRP.
Why is PRF harder to use on the scalp than elsewhere?
Because the treatment field is large relative to the deposit size. A scalp treatment is a systematic sweep of many small deposits over a long procedure, while PRF is thickening in the syringe throughout. The material you deliver at the end of the field is not the material you delivered at the start, and no technique removes that.
What would I need to change to offer PRF on the scalp?
Four things: a centrifuge in or beside the treatment room, two trained staff with the blood role and the patient role separated, a schedule block that commits the room for the whole procedure, and a validated working window measured with your own tubes. Silica-coated tubes clot substantially faster than plain plastic, so consumables set the clock.
How soon should a patient expect to see a change?
Around month three is the earliest honest reassessment point, and the reason is follicular cycling rather than shaft growth rate. Scalp hair grows about 0.35 mm per day, so elongation is not the limiting factor — recruiting follicles toward anagen and improving calibre in miniaturised follicles takes months to become visible.
Disclaimer
This article reflects the clinical opinions and experience of Tatiana Sarmiento, faculty, Empire Medical Training, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
